unusual cancer treatment that produced a high fever in his patients.
Although the treatment was unconventional, it turned out to be successful
surprisingly often. Should Coley's treatment be revived today? How else
might we jump-start the immune system? Find out about the hope for vaccine
treatments for cancer, as well as the status of Coley's fluid. This is the
second in a three-part series on unconventional approaches to cancer.
Guests: Don MacAdam, CEO of MBVax Bioscience in Ancaster, Ontario, Canada.
Online at MBvax.com <http://www.mbvax.com/>
Jonathan Serody, MD, Elizabeth Thomas Professor of Medicine, Microbiology
and Immunology in the Program in Stem Cell Transplantation. He is Director
of the LCCC Program in Malignant Hematology and Co-leader of the LCCC
Immunology Program at the University of North Carolina at Chapel Hill. The
photo is of Dr. Serody.
No comments:
Post a Comment